Skip to main content
. Author manuscript; available in PMC: 2010 Jun 16.
Published in final edited form as: Neuroscience. 2009 Mar 20;161(1):13–22. doi: 10.1016/j.neuroscience.2009.03.027

Figure 3. Effect of ICV AMD 3100 and CXCL12 on cocaine-induced ambulatory activity.

Figure 3

The selective CXCR4 antagonist AMD 3100 (2 μg/4 μl) was administered 60 minutes prior to administration of CXCL12 (25 ng/4 μl ICV), and then followed by saline or cocaine (20 mg/kg IP). Repeated measures ANOVA followed by Bonferroni post-hoc analysis showed a significant difference between the AMD/CXCL12/COC and the SAL/CXCL12/COC groups indicating that AMD 3100 blocked the CXCL12-induced increase in cocaine-stimulated ambulatory activity. Data are expressed as mean ± SEM beam breaks/five minute period. N= 7 – 10 per group as indicated in parentheses on the figure for each group. (AMD/CXCL12/COC vs. SAL/CXCL12/COC; *p<0.05, **p<0.01, ***p<0.001)